CD96
| T-cell surface protein tactile | ||
|---|---|---|
| other names |
Cell surface antigen CD96, T cell-activated increased late expression protein, CD96 |
|
| Properties of human protein | ||
| Mass / length primary structure | 585 amino acids , 65,634 Da | |
| Identifier | ||
| External IDs | ||
| Orthologue (human) | ||
| Entrez | 10225 | |
| Ensemble | ENSG00000153283 | |
| UniProt | P40200 | |
| Refseq (mRNA) | NM_001318889.1 | |
| Refseq (protein) | NP_001305818.1 | |
| PubMed search |
10225
|
|
CD96 (synonym T-cell surface protein tactile ) is a surface protein of the immunoglobulin superfamily .
properties
CD96 is produced by T cells and, to a very small extent, by B cells . It is a type I membrane protein . CD96 presumably serves the formation of cell contacts of activated T cells and NK cells in the later course of an immune response and is presumably involved in the antigen presentation . It is 20% homologous to CD226 and binds to CD155 .
CD96 mutations are associated with craniosynostosis . CD96 is a biomarker in acute myeloid leukemia and is being studied as a target . CD96 is an immune checkpoint .
Web links
Individual evidence
- ↑ L. Martinet, MJ Smyth: Balancing natural killer cell activation through paired receptors. In: Nature Reviews Immunology . Volume 15, Number 4, April 2015, pp. 243-254, doi : 10.1038 / nri3799 , PMID 25743219 .
- ^ Y. Ding, H. Gao, Q. Zhang: The biomarkers of leukemia stem cells in acute myeloid leukemia. In: Stem cell investigation. Volume 4, 2017, p. 19, doi : 10.21037 / sci.2017.02.10 , PMID 28447034 , PMC 5388677 (free full text).
- ^ WC Dougall, S. Kurtulus, MJ Smyth, AC Anderson: TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy. In: Immunological reviews. Volume 276, Number 1, March 2017, pp. 112-120, doi : 10.1111 / imr.12518 , PMID 28258695 .